Ali T. TaherZeynep KarakasElena CassinerioNoppadol SiritanaratkulAntonis KattamisAurelio MaggioStefano RivellaNorbert HollaenderBruyere MahuzierBrian GadbawYesim AydinokAmerican University of Beirut Medical CenterUniversità degli Studi di MilanoThe Children's Hospital of PhiladelphiaNational and Kapodistrian University of AthensNovartis Pharma S.A.S.Istanbul Üniversitesi Tıp FakültesiFaculty of Medicine, Siriraj Hospital, Mahidol UniversityNovartis International AGEge University Medical SchoolNovartis Pharmaceuticals CorporationUOSD MICI-A.O. Ospedali Riuniti “Villa Sofia-Cervello” Palermo2019-08-232019-08-232018-01-11Blood. Vol.131, No.2 (2018), 263-26515280020000649712-s2.0-85040441699https://repository.li.mahidol.ac.th/handle/20.500.14594/45268Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineEfficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a studyLetterSCOPUS10.1182/blood-2017-06-790121